Erratum: Synthesis and SAR of 5-amino- and 5-(aminomethyl)benzofuran histamine H3 receptor antagonists with improved potency (Journal of Medicinal Chemistry (2005) 48 (6482-6490) DOI: 10.1021/jm0504398);Synthesis and SAR of 5-amino- and 5-(aminomethyl)benzofuran histamine H3 receptor antagonists with improved potency

Journal of Medicinal Chemistry

Volumn 48, Issue 20, 2005, Pages 6482-6490

  Sun, Minghua ^a   Zhao, Chen ^a   Gfesser, Gregory A ^a   Thiffault, Christine ^a   Miller, Thomas R ^a   Marsh, Kennan ^a   Wetter, Jill ^a   Curtis, Michael ^a   Faghih, Ramin ^a   Esbenshade, Timothy A ^a   Hancock, Arthur A ^a   Cowart, Marlon ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [2 (2 METHYLPYRROLIDIN 1 YL)ETHYL]BENZOFURAN 5 YL (5 NITROPYRIDIN 2 YL)AMINE; 2 [2 (2 METHYLPYRROLIDIN 1 YL)ETHYL]BENZOFURAN 5 YL PYRIMIDIN 5 YLAMINE; 2 [2 (2 METHYLPYRROLIDIN 1 YL)ETHYL]BENZOFURAN 5 YLMETHYLPYRIMIDIN 2 YLAMINE; 5 (4 CYANOPHENYL) 2 [2 (2 METHYL 1 IMIDAZOLIDINYL)ETHYL]BENZOFURAN; 5 ETHYLPYRIMIDIN 2 YL 2 [2 (2 METHYLPYRROLIDIN 1 YL)ETHYL]BENZOFURAN 5 YLAMINE; 5 ETHYLPYRIMIDIN 2 YL 2 [2 (2 METHYLPYRROLIDIN 1 YL)ETHYL]BENZOFURAN 5 YLMETHYLAMINE; AMIODARONE; BENZOFURAN DERIVATIVE; HISTAMINE H3 RECEPTOR; HISTAMINE H3 RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; LIPIDOSIS; LIVER CELL; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

EID: 26444595613     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm201619h     Document Type: Erratum

References (49)

1. 3 receptor agonists and antagonists. Trends Pharmacol. Sci. 1998, 19, 177-183.
2. 3 receptor drugs. Nat. Rev. Drug Discovery 2005, 4, 107-120.
3. (c) Ma, P.; Zemmel, R. Value of Novelty? Nat. Rev Drug Discovery 2002, 1, 571-572.
4. (d) Hough, L. B. Genomics meets histamine receptors: New subtypes, new receptors. Mol. Pharmacol. 2001, 59, 415-419.
5. 3 receptor gene is cloned at last. Trends Pharmacol. Sci. 2000, 21, 11-12.
6. (a) Oda, T.; Morikawa, N.; Saito, Y.; Masuho, Y.; Matsumoto, S. Molecular cloning and characterization of a novel type of histamine receptor preferentially expressed in leukocytes. J. Biol. Chem. 2000, 275, 36781-36786.
7. 4) expressed in bone marrow. Mol. Pharmacol. 2001, 59, 420-426.
8. (a) Schwartz, J. C.; Arrang, J. M.; Garbarg, M.; Pollard, H.; Ruat, M. Histaminergic transmission in the mammalian brain. Physiol. Rev. 1991, 71, 1-51.
9. (b) Leurs, R.; Smit, M. J.; Timmerman, H. Molecular pharmacology aspects of histamine receptors. Pharmacol. Ther. 1995, 66, 413-463.
10. 3 receptor ligands GT-2331 and ciproxifan in a repeated acquisition avoidance response in the spontaneously hypertensive rat pup. Behav. Brain Res. 2002, 131, 151-161.
11. 3-receptor antagonist. J. Pharmacol. Exp. Ther. 1998, 287, 658-666.
12. 3 receptor antagonists A-304121 and A-317920: II. In vivo behavioral and neurophysiological characterization. J. Pharmacol. Exp. Ther. 2003, 305, 897-908.
13. 3 receptor antagonist. Eur. J. Pharmacol. 2004, 487, 183-197.
14. 3 antagonists in models of obesity. Inflammation Res. 2004, 53, S47-S48.
15. 3 receptor antagonists with human adrenal cytochrome P450 enzymes. Pharmacology 2002, 66, 128-135.
16. 3-receptor antagonists. Eur. J. Pharm. Sci. 2001, 13, 249-259.
17. 3 receptor antagonists. Bioorg. Med. Chem. Lett. 2003, 13, 1325-1328.
18. 3 receptor antagonists. Bioorg. Med. Chem. Lett. 2003, 13, 1767-1770.
19. 3 receptor antagonists. Bioorg. Med. Chem. Lett. 2002, 12, 3309-3312.
20. 3 receptor antagonists potently enhance cognition and attention. J. Med. Chem. 2005, 48, 38-55.
21. 3 receptor antagonist with drug-like properties. J. Pharmacol. Exp. Ther. 2005, 313, 165-175.
22. Zubia, E.; Rodriguez Luis, F.; Massanet, G. M.; Collado, I. G. An efficient synthesis of furanocoumarins. Tetrahedron 1992, 48, 4239-4246.
23. White, J. D.; Amedio, J. C. Total synthesis of geodiamolide A, a novel cyclodepsipeptide of marine origin. J. Org. Chem. 1989, 54, 736-738.
24. Sonogashira, K.; Tohda, Y.; Hagihara, N. A convenient synthesis of acetylenes: Catalytic substitutions of acetylenic hydrogen with bromoalkenes, iodoarenes, and bromopyridines. Tetrahedron Lett. 1975, 16, 4467-4470.
25. Aquila, B. M. A new synthesis of 8-methylpsoralen utilizing a palladium-copper catalyzed reaction to generate the furan ring and thus allowing for the generation of novel analogs in the 5′-position. Tetrahedron Lett. 1997, 38, 2795-2798.
26. Torres, J. C.; Pilli, R. A.; Vargas, M. D.; Violante, F. A.; Garden, S. J.; Pinto, A. C. Synthesis of 1-ferrocenyl-2-aryl(heteroaryl)-acetylenes and 2-ferrocenylindole derivatives via the Sonogashira-Heck-Cassar reaction. Tetrahedron 2002, 58, 4487-4492.
27. Wolfe, J. P.; Buchwald, S. L. Improved functional group compatibility in the palladium-catalyzed amination of aryl bromides. Tetrahedron Lett. 1997, 38, 6359-6362.
28. Ahman, J.; Buchwald, S. L. An improved method for the palladium-catalyzed amination of aryl triflates. Tetrahedron Lett. 1997, 38, 6363-6366.
29. Harris, M. C.; Geis, O.; Buchwald, S. L. Sequential N-arylation of primary amines as a route to alkyldiarylamines. J. Org. Chem. 1999, 64, 6019-6022.
30. Edgar, K. J.; Falling, S. N. An efficient and selective method for the preparation of iodophenols. J. Org. Chem. 1990, 55, 5287-5291.
31. Mulholland, G. K.; Qi-Huang Zheng, Q. A direct iodination method with iodine and silver triflate for the synthesis of SPECT and PET imaging agent precursors. Synth. Commun. 2001, 31, 3059-3068.
32. 3 antagonists: 2-Aminoethylbenzofurans. Bioorg. Med. Chem. Lett. 2004, 14, 689-693.
33. (a) Huang, X.; Buchwald, S. L. New ammonia equivalents for the Pd-catalyzed amination of aryl halides. Org. Lett. 2001, 3, 3417-3419.
34. (b) Harris, M. C.; Huang, X.; Buchwald, S. L. Improved functional group compatibility in the palladium-catalyzed synthesis of arylamines. Org. Lett. 2002, 4, 2885-2888.
35. (c) Lee, S.; Jorgensen, M.; Hartwig, J. F. Palladium-catalyzed synthesis of arylamines from aryl halides and lithium bis-(trimethylsilyl)amine as an ammonia equivalent. Org. Lett. 2001, 3, 2729-2732.
36. 3 receptor antagonists A-304121 and A-317920: I. In vitro pharmacological effects. J. Pharmacol. Exp. Ther. 2003, 305, 887-896.
37. 3 receptor antagonists: 4-(Aminoalkoxy)benzylamines. J. Med. Chem. 2003, 46, 3938-3944.
38. 3 antagonist. Br. J. Pharmacol, 2004, 143, 649-661.
39. 3 receptor antagonists, preparation and therapeutic uses. US patent application, US 2004/0110748 A1.
40. 3 receptor antagonists, preparation and therapeutic uses. PCT patent application WO 2004/026837 A2.
41. (a) Mingeot-Leclercq, M. P.; Laurent, G.; Tulkens, P. M. Biochemical mechanism of aminoglycoside-induced inhibition of phosphatidylcholine hydrolysis by lysosomal phospholipases. Biochem. Pharmacol. 1988, 37, 591-599.
42. (b) Mingeot-Leclercq, M. P.; Schanck, A.; Ronveaux-Dupal, M. F.; Deleers, M.; Brasseur, R.; Ruysschaert, J. M.; Tulkens, P. M. Ultrastructural, physicochemical and conformational study of the interactions of gentamicin and bis(beta-diethylaminoethylether)hexestrol with negatively charged phospholipid bilayers. Biochem. Pharmacol. 1989, 38, 729-741.
43. Montenez, J. P.; Van Bambeke, F.; Piret, J.; Brasseur, R.; Tulkens, P. M.; Mingeot-Leclercq, M. P. Interactions of macrolide antibiotics (erythromycin A, roxithromycin, erythromycylamine [dirithromycin], and azithromycin) with phospholipids: Computer-aided conformational analysis and studies on acellular and cell culture models. Toxicol. Appl. Pharmacol. 1999, 156, 129-140.
44. (a) Ulrich, R. G.; Kilgore, K. S.; Sun, E. L.; Cramer, C. T.; Ginsburg, L. C. An in vitro fluorescence assay for the detection of drug-induced cytoplasmic lamellar bodies. Toxicol. Methods 1991, 1, 89-105.
45. (b) Gum, R. J.; Hickman, D.; Fagerland, J. A.; Heindel, M. A.; Gagne, G. D.; Schmidt, J. M.; Michaelides, M. R.; Davidsen, S. K.; Ulrich, R. G. Analysis of two matrix metalloproteinase inhibitors and their metabolites for induction of phospholipidosis in rat and human hepatocytes. Biochem. Pharmacol. 2001, 62, 1661-1673.
46. Mortuza, G. B.; Neville, W. A.; Delaney, J.; Waterfield, C. J.; Camilleri, P. Characterization of a potential biomarker of phospholipidosis from amiodarone-treated rats. Biochim. Biophys. Acta 2003, 1631, 136-146.
47. (a) Elliget, K. A.; Kolaja, G. J. Preparation of primary cultures of rat hepatocytes suitable for in vitro toxicity testing. J. Tissue Culture Methods 1983, 8, 1-6.
48. (b) Seglen, P. O. Preparation of isolated rat liver cells. Methods Cell Biol. 1976, 13, 29-83.
49. Gagne, G. D.; Gum, R.; Jolly, R. A.; Heindel, M. A.; Fagerland, J. A. A quantitative image-based in vitro assay for induction of phospholipidosis in hepatocytes. Microsc. Microanal. 2002, 8 (Suppl. 2), 740CD-741CD.